We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Second Lafora Disease Gene Identified

By Biotechdaily staff writers
Posted on 07 Oct 2003
Researchers have identified a second gene that causes Lafora disease (LD), the most severe form of teenage-onset epilepsy, and now explains the genetic basis for the disease in more than 90% of families with an afflicted child.

Lafora disease is a form of progressive myoclonus epilepsy beginning from age six to 19; characterized by generalized tonic-clonic seizures, resting and action myoclonus, ataxia, dementia, and classic EEG findings, including polyspike and wave discharges; basophilic cytoplasmic inclusion bodies present in portions of the brain, the liver, and skin, as well as the duct cells of the sweat glands. Death usually occurs within 10 years of onset. Lafora disease is passed by autosomal recessive inheritance.

In a study published in the September 2003 issue of Nature Genetics, investigators from the University of Toronto (Canada; www.utoronto.ca) reported the discovery of the NHLRC1 gene, which is the second gene found to cause Lafora disease. The other gene, EPM2A, was discovered five years ago.

"The newly discovered LD gene, named NHLRC1, produces a protein thought to be involved in marking other proteins for destruction in the cell. Our early data suggest that the EPM2A and NHLRC1 genes work together to safeguard neurons against accumulating too many carbohydrates. If either of the genes is missing, the result is epilepsy,” explained senior author Dr. Stephen Scherer, associate professor of molecular and medical genetics at the University of Toronto. "Importantly, we can now explain Lafora disease in 90% of families, and for the remaining 10%, we think there is a third yet-to-be-identified disease gene.”




Related Links:
University of Toronto

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Clinical Informatics Platform
CLARION™
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group

Latest BioResearch News

D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
07 Oct 2003  |   BioResearch

New Genetic Cause Identified for Neurodevelopmental Disorder
07 Oct 2003  |   BioResearch

New Genetic Discovery Could Support Precision Diabetes Care
07 Oct 2003  |   BioResearch